HOME >> BIOLOGY >> NEWS
Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID

Worcester, Mass. June 28, 2007 -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID for Non-Hodgkins lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkins Lymphoma of any of the Phase 3 Non-Hodgkins Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007.

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkins Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patients own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells. The BiovaxID Phase 3 clinical trial is being conducted at
'"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
28-Jun-2007


Page: 1 2

Related biology news :

1. Biovest International submits amendment request to FDA for use of molecular remission data
2. AutovaxID-C introduced by Biovest International
3. Biovest International announces that it will report new follow-up data
4. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
5. ESA announces 2007 award recipients
6. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
7. Conservation Leadership Program announces 2007 awardees
8. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
9. Revolutionary global environment fund announces $50M expansion
10. Cell Press announces new partnership with the American Society of Human Genetics
11. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... ... November 19, 2019 , ... The inaugural Cell & ... in New York City. The one-day event will be chaired by Dr Aiman Shalabi, ... in the space. , “We are witnessing significant innovation in cell and gene ...
(Date:11/14/2019)... , ... November 13, 2019 , ... Personalized Stem ... first patients in an FDA approved clinical trial for stem cell treatment of ... formation of the company as a subsidiary of VetStem Biopharma. , In July of ...
(Date:11/12/2019)... ... November 12, 2019 , ... G5, the ... digital advertising performance up to 25% and reduces cost-per-click by as much as ... advanced multi-touch attribution (MTA) to predict best advertising outcomes and automatically allocate daily ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... ... November 08, 2019 , ... PathAI, a ... today announced the results of analyses examining the severity of nonalcoholic steatohepatitis ... selonsertib studies (STELLAR). Strong correlations were demonstrated between AI-powered and manual pathologist ...
(Date:11/5/2019)... ... 2019 , ... Ole, a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. ... energy level and his willingness to play were normal, it was clear that he was ... VCA Emergency Animal Hospital and Referral Center in San Diego, California. Dr. Mullen ...
(Date:10/30/2019)... ... October 30, 2019 , ... Western University ... roles innovation and technology play in educating the next generation of health care ... opportunities and presentations by WesternU administrators and representatives of companies working with the ...
(Date:10/22/2019)... ... ... nQ Medical, Inc. of Cambridge, MA, was recognized in the top 5 ... at a showcase event yesterday in Los Angeles. nQ competed against 3,500 early-stage U.S. ... near-term growth projections to be named one of the most fundable companies in America. ...
Breaking Biology Technology:
Cached News: